Cite
HARVARD Citation
Hassan, R. et al. (n.d.). 3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial. European journal of cancer. pp. S639-. [Online].